CO2022017026A2 - Anticuerpo humanizado anti– receptor de igf–1 - Google Patents
Anticuerpo humanizado anti– receptor de igf–1Info
- Publication number
- CO2022017026A2 CO2022017026A2 CONC2022/0017026A CO2022017026A CO2022017026A2 CO 2022017026 A2 CO2022017026 A2 CO 2022017026A2 CO 2022017026 A CO2022017026 A CO 2022017026A CO 2022017026 A2 CO2022017026 A2 CO 2022017026A2
- Authority
- CO
- Colombia
- Prior art keywords
- igf
- antibody
- humanized anti
- receptor
- igf11
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020096344 | 2020-06-02 | ||
| PCT/JP2021/020890 WO2021246413A1 (ja) | 2020-06-02 | 2021-06-01 | 抗ｉｇｆ－１受容体ヒト化抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022017026A2 true CO2022017026A2 (es) | 2022-12-09 |
Family
ID=78831168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0017026A CO2022017026A2 (es) | 2020-06-02 | 2022-11-28 | Anticuerpo humanizado anti– receptor de igf–1 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20250263489A1 (https=) |
| EP (1) | EP4159860A4 (https=) |
| JP (2) | JPWO2021246413A1 (https=) |
| KR (1) | KR20230006006A (https=) |
| CN (1) | CN115605594A (https=) |
| AR (1) | AR122499A1 (https=) |
| AU (1) | AU2021282629A1 (https=) |
| BR (1) | BR112022022030A2 (https=) |
| CA (1) | CA3176119A1 (https=) |
| CL (1) | CL2022003399A1 (https=) |
| CO (1) | CO2022017026A2 (https=) |
| IL (1) | IL296519A (https=) |
| MX (1) | MX2022015133A (https=) |
| TW (1) | TW202210513A (https=) |
| WO (1) | WO2021246413A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230357384A1 (en) * | 2020-06-18 | 2023-11-09 | Nextcure, Inc. | Compositions and methods for modulating flrt3 mediated signal transduction |
| CN114561337B (zh) * | 2022-03-09 | 2023-10-03 | 广州源井生物科技有限公司 | 一种提高HepG2细胞克隆形成率的单克隆增强培养基和方法 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7538195B2 (en) * | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| WO2007064911A1 (en) * | 2005-12-02 | 2007-06-07 | Biogen Idec Inc. | Anti-mouse cd20 antibodies and uses thereof |
| US20150353643A1 (en) * | 2013-09-24 | 2015-12-10 | Universite De La Mediterranee - Aix-Marseille Ii | Anti-cd277 antibodies and uses thereof |
| AU2013251312B2 (en) * | 2012-04-27 | 2018-03-22 | Takeda Pharmaceutical Company Limited | Anti-GCC antibody molecules and use of same to test for susceptibility to GCC-targeted therapy |
| JP2018139530A (ja) * | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 |
| AR112600A1 (es) * | 2017-05-30 | 2019-11-20 | Teijin Pharma Ltd | Anticuerpo anti-receptor de igf-i |
| WO2019148410A1 (en) * | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1 antibodies |
| JP2021513367A (ja) * | 2018-02-12 | 2021-05-27 | ダイアベーツ−フリー， インコーポレイテッド | 改善されたアンタゴニスト的抗ヒトｃｄ４０モノクローナル抗体 |
| GB201803892D0 (en) * | 2018-03-12 | 2018-04-25 | Ultrahuman Six Ltd | C-met binding agents |
| BR112021010479A2 (pt) * | 2018-12-03 | 2021-11-16 | Teijin Pharma Ltd | Anticorpo humanizado anti-receptor de igf-i ou fragmento ou derivado do mesmo, molécula de ácido nucleico, vetor de clonagem ou vetor de expressão, célula recombinante, processo para produção de um anticorpo humanizado anti-receptor de igf-i ou fragmento ou derivado do mesmo, e, composição farmacêutica |
-
2021
- 2021-06-01 CN CN202180039577.1A patent/CN115605594A/zh active Pending
- 2021-06-01 IL IL296519A patent/IL296519A/en unknown
- 2021-06-01 BR BR112022022030A patent/BR112022022030A2/pt unknown
- 2021-06-01 MX MX2022015133A patent/MX2022015133A/es unknown
- 2021-06-01 KR KR1020227042511A patent/KR20230006006A/ko active Pending
- 2021-06-01 JP JP2022528850A patent/JPWO2021246413A1/ja active Pending
- 2021-06-01 US US18/007,606 patent/US20250263489A1/en active Pending
- 2021-06-01 TW TW110119805A patent/TW202210513A/zh unknown
- 2021-06-01 EP EP21817253.4A patent/EP4159860A4/en active Pending
- 2021-06-01 AR ARP210101492A patent/AR122499A1/es unknown
- 2021-06-01 WO PCT/JP2021/020890 patent/WO2021246413A1/ja not_active Ceased
- 2021-06-01 CA CA3176119A patent/CA3176119A1/en active Pending
- 2021-06-01 AU AU2021282629A patent/AU2021282629A1/en active Pending
-
2022
- 2022-11-28 CO CONC2022/0017026A patent/CO2022017026A2/es unknown
- 2022-12-01 CL CL2022003399A patent/CL2022003399A1/es unknown
-
2024
- 2024-02-28 JP JP2024028737A patent/JP2024054410A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024054410A (ja) | 2024-04-16 |
| EP4159860A4 (en) | 2024-09-25 |
| CL2022003399A1 (es) | 2023-08-11 |
| CN115605594A (zh) | 2023-01-13 |
| EP4159860A1 (en) | 2023-04-05 |
| JPWO2021246413A1 (https=) | 2021-12-09 |
| AR122499A1 (es) | 2022-09-14 |
| WO2021246413A1 (ja) | 2021-12-09 |
| AU2021282629A1 (en) | 2022-12-01 |
| TW202210513A (zh) | 2022-03-16 |
| US20250263489A1 (en) | 2025-08-21 |
| BR112022022030A2 (pt) | 2023-01-17 |
| IL296519A (en) | 2022-11-01 |
| CA3176119A1 (en) | 2021-12-09 |
| MX2022015133A (es) | 2023-01-11 |
| KR20230006006A (ko) | 2023-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022017026A2 (es) | Anticuerpo humanizado anti– receptor de igf–1 | |
| CL2021001446A1 (es) | Anticuerpo humanizado anti-receptor de igf-i | |
| Chao et al. | SYN023, a novel humanized monoclonal antibody cocktail, for post-exposure prophylaxis of rabies | |
| JP2024054410A5 (https=) | ||
| CO2019007844A2 (es) | Anticuerpo anti-receptor de transferrina humana novedoso capaz de penetrar la barrera hematoencefálica | |
| AR072985A1 (es) | Tratamiento para una enfermedad autoinmune o trastorno inflamatorio, procedimiento, anticuerpo, proteina de union | |
| PE20141398A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| CL2021001705A1 (es) | Anticuerpos humanizados contra la región de la cadena beta de la 9na familia trbv9 del tcr humano, y sus métodos de uso. | |
| MX2022005949A (es) | Anticuerpos anti-ror-2 y metodos de uso. | |
| AR123671A1 (es) | Anticuerpo fn14 anti-humano | |
| MX2024011894A (es) | Metodos de tratamiento de trastornos usando anticuerpos anti-receptor de peptido natriuretico 1 (npr1) | |
| WO2022174103A3 (en) | Monoclonal antibodies specific for human ror1 | |
| RU2018120245A (ru) | Однодоменные антитела, направленные против внутриклеточных антигенов | |
| Kamen et al. | Exercise effects upon reflex time components in weight lifters and distance runners. | |
| Leary | Autoimmune epilepsy in children: unraveling the mystery | |
| MX2024005057A (es) | Anticuerpo de receptor 4 de efrina tipo a (anti-epha4). | |
| Chumbe et al. | Characteristics of an antibody profile associated with protection against hepatitis C virus reinfection in a high-risk cohort | |
| WO2020113199A1 (en) | Recombinant hiv env polypeptides and their use | |
| Wong et al. | Establishing CD4 thresholds for highly active antiretroviral therapy initiation in a cohort of HIV-infected adult Chinese in Hong Kong | |
| Idowu et al. | The COVID-19 pandemic in sub-Saharan Africa: The significance of presumed immune sufficiency | |
| ES2649536T3 (es) | Anticuerpos contra el virus de la influenza y métodos para su uso | |
| Luchytskyy et al. | Erectile dysfunction in men with diabetes (literature review) Part 1 | |
| IuA et al. | A common antigenic epitope in influenza A virus (H1, H2, H5, H6) hemagglutinin | |
| Thi et al. | Timing of antiretroviral therapy and TB treatment outcomes in patients with TB-HIV in Myanmar | |
| AR131562A1 (es) | Anticuerpos anti-il-11ra para el tratamiento de la enfermedad ocular tiroidea |